Skip to main content
OpenTrials
Completed

NCT Number: NCT03010397

Progression of Diabetic Retinopathy. Identification of Signs and Surrogate Outcomes

Progression of Diabetic Retinopathy. Identification of Signs and Surrogate outcomes (PROGRESS)

Completed

Looking for future studies?

Notify Me

Key information

Age range

35 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Aibili-Cec

Coimbra, 3000-548, Portugal

About this study

The global aim of this study is to improve the current knowledge of diabetic retinopathy (DR) progression. We aim to characterize both functionally and morphologically initial DR stages and to identify patients at risk of progression to centre involving macular oedema (CME) and/or proliferative diabetic retinopathy (PDR). We want to identify imaging patterns and characteristics that might be used as prognostic biomarkers for DR progression.

For this, ischemia and blood-retinal barrier alteration will be assessed using non-invasive retinal imaging methodologies. SD-OCT with layer-by-layer segmentation will be performed. Furthermore, a state-of-the-art methodology with OCT-Angiography will be used for identification of areas of capillary drop-out and leakage areas will be identified on SD-OCT without the need of a dye injection. In a subgroup of patients we will study neurodegeneration patterns using multifocal ERG examination.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Type 2 diabetes mellitus according to 1985 WHO criteria
  • Aged between 35 years and 80 at baseline in the retrospective period
  • NPDR level < 20 (MA absent) or Mild NPDR (levels 20 to 35, based on ETDRS criteria- 7 fields CFP) at baseline
  • BCVA ≥ 75 letters (≥ 20/32) at baseline (ETDRS charts)
  • Informed Consent

Exclusion criteria

  • Inadequate ocular media and/ or pupil dilatation that interfere with fundus examinations
  • HbA1C > 10 % at the Screening or previous 6 months in the previous prospective study

Treatment and study plan

Primary outcomes

  1. Phenotypic classification of DR in a 5-year period

    Time frame: 5 years

    Presence CME (Central Macular Edema) or PDR (Proliferative Diabetic Retinopathy)

Secondary outcomes

  1. DR severity level

    Time frame: 5 years

    ETDRS grading

  2. Retinal thickness analysis

    Time frame: 5 years

    Retinal thickness (RT) in central subfield, inner and outer rings, assessed by SD-OCT and using layer-by-layer segmentation

  3. Ellipsoid zone analysis

    Time frame: 5 years

    Degree of integrity of the ellipsoid zone, assessed by SD-OCT

  4. Choroidal thickness analysis

    Time frame: 5 years

    Choroidal thickness assessed by Enhanced Depth Imaging (EDI) SD-OCT

  5. SD- OCT- Angiography analysis

    Time frame: 5 years

    Vessel analysis, assessed by SD-OCT OCT-Angiography

  6. OCT-Leakage analysis

    Time frame: 5 years

    LOR (low optical reflectivity) ratio in central subfield, inner and outer ring for assessment of BRB breakdown, assessed by OCT-Leakage

  7. Retinal thickness quantification

    Time frame: 5 years

    Retinal nerve fiber layer thickness (RNFL) and ganglion cells layer (GCL) + inner plexiform layer thickness (IPL) thickness, assessed by layer-by-layer SD-OCT

  8. mfERG assessement

    Time frame: 5 years

    P1 implicit time and P1 amplitude by ring

Sponsors and collaborators

Lead sponsor

Association for Innovation and Biomedical Research on Light and Image

Other

Registry information

Official study title

PROGRESS - Progression of Diabetic Retinopathy. Identification of Signs and Surrogate Outcomes

Acronym: PROGRESS

Important dates

Study start
2016
Primary completion
2017
Study completion
2019
First posted
Jan 5, 2017
Registry last updated
Mar 24, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.